MED vs NUS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

MED

46.5
AI Score
VS
MED Wins

NUS

44.1
AI Score

Investment Advisor Scores

MED

47score
Recommendation
HOLD

NUS

44score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED NUS Winner
Revenue 152.43M 320.61M NUS
Net Income -5.22M 1.84M NUS
Gross Margin 69.0% 66.9% MED
Net Margin -3.4% 0.6% NUS
Operating Income -7.62M 4.03M NUS
ROE -2.7% 0.2% NUS
ROA -2.0% 0.1% NUS
Total Assets 260.40M 1.38B NUS
Cash 71.91M 198.65M NUS
Current Ratio 4.86 2.03 MED
Free Cash Flow -108,000 -17.63M MED

Relative Price Performance (Last 90 Days)

MED 1M: -11.1% · 3M: -10.7% NUS 1M: +3.0% · 3M: -28.2%

Current Technical Phase

MED

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.7%), weak momentum, RSI 39

RSI (14): 38.7 · Price: $9.74

NUS

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -11.0%) with fading momentum, RSI 46

RSI (14): 46.1 · Price: $5.16

Fundamentals Snapshot

Metric MED NUS
Market Cap
Forward P/E -16.5 3.9
Trailing P/E 4.8
Revenue (TTM)
Revenue Growth -0.3% -0.1%
Gross Margin 0.7% 0.7%
Operating Margin -0.1% 0.0%
EPS -1.82 1.08
Dividend Yield 0.05%

Frequently Asked Questions

Based on our detailed analysis, MED is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.